SK Biopharmaceuticals settles first US patent dispute over Xcopri
- Source
- The Korea Herald - Business
- Source link
- https://www.koreaherald.com/article/10845774
- Published
- 2026-08-19 17:03:21
- Discovered by ProcIntel
- 2026-08-19 11:21:37
- Category
- Procurement & Supply Chain News
- Geography
- South Korea
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
SK Biopharmaceuticals said Wednesday it has reached a settlement with Indian generic drugmaker MSN Laboratories in a United States patent dispute over cenobamate, its epilepsy treatment sold as Xcopri in the US, laying the groundwork for continued patent protection for the drug in the world’s largest pharmaceutical market. Although the terms of the agreement were not disclosed, it marks the first resolution in SK Biopharmaceuticals’ strategy to defend Xcopri’s intellectual property rights agains
Procurement Relevance Gate
- geographic_exposure (weight 8) — matched on "1 linked geography"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Not Assessed — this Signal did not pass the Procurement Relevance Gate, or is fictional/excluded test data.